Eledon Pharmaceuticals, Inc. (ELDN) Current Ratio
- Current ratio · latest quarter: Value 7.90×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.90× | Current assets / current liabilities. $93.09M ÷ $11.79M ≈ 7.90× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 93.09M USD | Assets, Current |
| Current obligations | 11.79M USD | Liabilities, Current |
| Cash and equivalents | 6.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.21M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $93.09M | $11.79M | $6.80M | (m) | (m) | (m) | $3.21M | (m) | 7.90× |
| 2026-03-31 | $113.57M | $13.46M | $6.15M | (m) | (m) | (m) | $6.58M | (m) | 8.44× |
| 2025-12-31 | $135.69M | $18.34M | $22.81M | (m) | (m) | (m) | $3.63M | (m) | 7.40× |
| 2025-09-30 | $96.30M | $14.30M | $3.67M | (m) | (m) | (m) | $4.63M | (m) | 6.74× |
| 2025-06-30 | $111.40M | $13.72M | $5.74M | (m) | (m) | (m) | $5.83M | (m) | 8.12× |
| 2025-03-31 | $127.72M | $9.19M | $8.50M | (m) | (m) | (m) | $2.90M | (m) | 13.91× |
| 2024-12-31 | $143.73M | $11.58M | $20.55M | (m) | (m) | (m) | $5.83M | (m) | 12.42× |
| 2024-09-30 | $81.51M | $12.49M | $6.75M | (m) | (m) | (m) | $5.86M | (m) | 6.53× |
| 2024-06-30 | $87.22M | $6.03M | $26.04M | (m) | (m) | (m) | $2.15M | (m) | 14.48× |
| 2024-03-31 | $47.98M | $4.25M | $5.66M | (m) | (m) | (m) | $1.86M | (m) | 11.30× |
| 2023-12-31 | $56.13M | $3.90M | $4.61M | (m) | (m) | (m) | $967.00K | (m) | 14.41× |
| 2023-09-30 | $62.99M | $2.90M | $3.67M | (m) | (m) | (m) | $465.00K | (m) | 21.73× |
| 2023-06-30 | $73.62M | $4.90M | $40.95M | (m) | (m) | (m) | $2.20M | (m) | 15.02× |
| 2023-03-31 | $48.90M | $5.48M | $46.48M | (m) | (m) | (m) | $2.85M | (m) | 8.93× |
| 2022-12-31 | $59.52M | $6.47M | $56.41M | (m) | (m) | (m) | $2.20M | (m) | 9.19× |
| 2022-09-30 | $67.56M | $6.28M | $65.89M | (m) | (m) | (m) | $3.86M | (m) | 10.76× |
| 2022-06-30 | $72.79M | $3.28M | $70.46M | (m) | (m) | (m) | $1.32M | (m) | 22.22× |
| 2022-03-31 | $79.33M | $2.96M | $76.68M | (m) | (m) | (m) | $1.03M | (m) | 26.82× |
| 2021-12-31 | $88.35M | $4.40M | $84.83M | (m) | (m) | (m) | $1.81M | (m) | 20.07× |
| 2021-09-30 | $95.56M | $4.05M | $94.04M | (m) | (m) | (m) | $1.60M | (m) | 23.62× |
| 2021-06-30 | $102.58M | $2.68M | $101.13M | (m) | (m) | (m) | $857.00K | (m) | 38.32× |
| 2021-03-31 | $110.24M | $4.21M | $108.58M | (m) | (m) | (m) | $1.51M | (m) | 26.21× |
| 2020-12-31 | $115.63M | $2.48M | $114.19M | (m) | (m) | (m) | $1.37M | (m) | 46.57× |
| 2020-09-30 | $115.10M | $6.13M | $114.46M | (m) | (m) | (m) | $758.00K | (m) | 18.78× |
| 2020-06-30 | $9.76M | $1.10M | (m) | (m) | (m) | (m) | $150.00K | (m) | 8.90× |
| 2020-03-31 | $12.87M | $1.88M | (m) | (m) | (m) | (m) | $741.00K | (m) | 6.85× |
| 2019-12-31 | $9.97M | $1.32M | $8.79M | (m) | (m) | (m) | $329.00K | (m) | 7.54× |
| 2019-09-30 | $12.30M | $1.66M | (m) | (m) | (m) | (m) | $256.00K | (m) | 7.40× |
| 2019-06-30 | $15.18M | $1.95M | (m) | (m) | (m) | (m) | $753.00K | (m) | 7.79× |
| 2019-03-31 | $10.32M | $3.24M | (m) | (m) | (m) | (m) | $480.00K | (m) | 3.18× |
| 2018-12-31 | $14.28M | $2.53M | $12.97M | (m) | (m) | (m) | $689.00K | (m) | 5.63× |
| 2017-09-30 | $21.04M | $2.31M | $19.09M | (m) | (m) | (m) | $189.00K | (m) | 9.12× |
| 2017-06-30 | $24.84M | $3.16M | $22.50M | (m) | (m) | (m) | $374.00K | (m) | 7.86× |
| 2017-03-31 | $25.63M | $2.42M | $24.40M | (m) | (m) | (m) | $276.00K | (m) | 10.60× |
| 2016-09-30 | $36.33M | $6.34M | $18.63M | (m) | (m) | (m) | $886.00K | (m) | 5.73× |
| 2016-06-30 | $46.19M | $7.82M | $12.16M | (m) | (m) | (m) | $1.85M | (m) | 5.91× |
| 2016-03-31 | $56.99M | $6.18M | $14.30M | (m) | (m) | (m) | $1.89M | (m) | 9.23× |
| 2015-12-31 | $67.17M | $6.16M | $24.02M | (m) | (m) | (m) | $1.21M | (m) | 10.90× |
| 2015-09-30 | $76.86M | $5.66M | $33.17M | (m) | (m) | (m) | $1.65M | (m) | 13.59× |
| 2015-06-30 | $86.76M | $4.65M | $59.08M | (m) | (m) | (m) | $1.70M | (m) | 18.67× |
| 2015-03-31 | $96.33M | $5.75M | $94.16M | (m) | (m) | (m) | $3.43M | (m) | 16.74× |
| 2014-12-31 | $107.51M | $4.24M | $105.26M | (m) | (m) | (m) | $765.00K | (m) | 25.34× |
| 2014-09-30 | $106.72M | $5.37M | $105.46M | (m) | (m) | (m) | $2.89M | (m) | 19.87× |
| 2013-12-31 | $32.18M | $2.21M | $31.75M | (m) | (m) | (m) | $5.00K | (m) | 14.57× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |